Cantor Fitzgerald Weighs in on Gilead Sciences FY2026 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Gilead Sciences in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Gould forecasts that the biopharmaceutical company will post earnings of $9.39 per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $125.00 price objective on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

GILD has been the subject of a number of other research reports. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a report on Thursday, March 27th. Wells Fargo & Company increased their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, April 25th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price for the company in a report on Thursday, February 13th. Finally, Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $110.55.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $109.30 on Tuesday. The stock has a market capitalization of $135.96 billion, a price-to-earnings ratio of 295.41, a PEG ratio of 0.71 and a beta of 0.29. Gilead Sciences has a twelve month low of $62.69 and a twelve month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The stock has a 50-day moving average of $105.40 and a 200 day moving average of $101.91.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) earnings per share. The company’s revenue was down .3% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Redwood Financial Network Corp increased its stake in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 98 shares during the last quarter. Argentarii LLC increased its stake in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock valued at $380,000 after acquiring an additional 99 shares during the last quarter. Nicolet Advisory Services LLC increased its stake in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 100 shares during the last quarter. Peak Financial Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after acquiring an additional 100 shares during the last quarter. Finally, Perkins Coie Trust Co increased its stake in shares of Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares of the company’s stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 43,000 shares of company stock valued at $4,630,310 in the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.89%. Gilead Sciences’s payout ratio is 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.